Table 3.
In vitro activity of aztreonam/avibactam and ceftazidime/aztreonam/avibactam against recombinant K. pneumoniae strains (mg/L)
| Strain | β-Lactamases | MLST ST | OmpK35/36 | MIC (mg/L) |
|
|---|---|---|---|---|---|
| ATM/AVI | CAZ/ATM/AVI | ||||
| Kp040 | IMP-4, DHA-1 | new | WT/WT | ≤0.25 | ≤0.125 |
| Kp040-CMY | IMP-4, DHA-1, CMY-16 | ≤0.25 | ≤0.125 | ||
| Kp040-R150 | IMP-4, DHA-1, CMY-16 (Tyr150Ser) | 4 | ≤0.125 | ||
| Kp040-R346 | IMP-4, DHA-1, CMY-16 (Asn346His) | 2 | ≤0.125 | ||
| Kp189 | NDM-7, CTX-M-15, SHV-11, TEM-1, OXA-1 | ST16 | WT/WT | ≤0.25 | ≤0.125 |
| Kp189-CMY | NDM-7, CTX-M-15, SHV-11, TEM-1, OXA-1, CMY-16 | ≤0.25 | ≤0.125 | ||
| Kp189-R150 | NDM-7, CTX-M-15, SHV-11, TEM-1, OXA-1, CMY-16 (Tyr150Ser) | 4 | ≤0.125 | ||
| Kp189-R346 | NDM-7, CTX-M-15, SHV-11, TEM-1, OXA-1, CMY-16 (Asn346His) | 4 | ≤0.125 | ||
| Kp214 | NDM-5, OXA-181, CTX-M-15, SHV-11, TEM-1 | ST147 | MT (ISEcp1 ins)/MT (135 DT ins) | ≤0.25 | ≤0.125 |
| Kp214-CMY | NDM-5, OXA-181, CTX-M-15, SHV-11, TEM-1, CMY-16 | ≤0.25 | ≤0.125 | ||
| Kp214-R150 | NDM-5, OXA-181, CTX-M-15, SHV-11, TEM-1, CMY-16 (Tyr150Ser) | 128 | 32 | ||
| Kp214-R346 | NDM-5, OXA-181, CTX-M-15, SHV-11, TEM-1, CMY-16 (Asn346His) | 64 | 32 | ||
| Kp231 | NDM-1, OXA-48, CTX-M-15, SHV-11, OXA-1 | ST377 | MT (IS1 ins)/WT | ≤0.25 | ≤0.125 |
| Kp231-CMY | NDM-1, OXA-48, CTX-M-15, SHV-11, OXA-1, CMY-16 | ≤0.25 | ≤0.125 | ||
| Kp231-R150 | NDM-1, OXA-48, CTX-M-15, SHV-11, OXA-1, CMY-16 (Tyr150Ser) | 128 | 32 | ||
| Kp231-R346 | NDM-1, OXA-48, CTX-M-15, SHV-11, OXA-1, CMY-16 (Asn346His) | 32 | 32 | ||
| Kp518 | KPC-2, SHV-11 | ST258 | MT (stop)/WT | ≤0.25 | ≤0.125 |
| Kp518-CMY | KPC-2, SHV-11, CMY-16 | ≤0.25 | ≤0.125 | ||
| Kp518-R150 | KPC-2, SHV-11, CMY-16 (Tyr150Ser) | 32 | ≤0.125 | ||
| Kp518-R346 | KPC-2, SHV-11, CMY-16 (Asn346His) | 16 | ≤0.125 | ||
ATM, aztreonam; AVI, avibactam; CAZ, ceftazidime; MT, mutant type; ins, insertion; DT ins, aspartate and threonine insertion.